Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Diverse hands
The FDA expects studies can be conducted with diversity action plans 'in most cases.' • Source: Shutterstock

More from Diversity & Inclusion

More from Clinical Trials